Triphala is a classical Ayurvedic three-fruit formulation made from the dried fruit material of Amalaki (Phyllanthus emblica; synonym Emblica officinalis), Bibhitaki (Terminalia bellirica), and Haritaki (Terminalia chebula). The equal-part powdered preparation is described in the Ayurvedic Formulary of India. Classical texts also contain Triphala-based rasayana regimens with particular proportions and adjuvants, so those regimens should not automatically be treated as identical to every modern capsule, extract, or commercial powder.
The modern evidence is uneven. Human trials are available for oral hygiene, body-weight outcomes, short-term safety, and some metabolic measures, but many broader claims rest mainly on laboratory or animal experiments. Formulation, dose, and study population vary substantially, limiting direct comparison.
Classical Ayurvedic Position
Triphala has an established place in Ayurvedic rasayana practice. The Charaka Samhita, Chikitsa Sthana, Rasayana Adhyaya, includes Triphala-based regimens in its discussion of rejuvenative care. This classical use concerns an individualized regimen involving the fruits and specified vehicles; it is not a modern guarantee that a fixed commercial dose will prevent or treat every condition associated with ageing.
In practical Ayurveda, Triphala is commonly selected when bowel regularity, digestion, and long-term constitutional support are being considered. Amount, timing, vehicle, and duration depend on digestive strength, stool pattern, age, illness, and the wider treatment plan. A qualified Ayurvedic practitioner should distinguish a gentle supportive use from therapeutic purgation or treatment of a diagnosed gastrointestinal disorder.
Digestive Regulation: Traditional Use with Limited Clinical Confirmation
Digestive and bowel-regulating use is the best-known traditional application. A 45-day clinical study involving 160 people compared three Triphala preparations and reported improvements in stool amount, frequency, consistency, flatulence, belching, abdominal pain, and related symptom scores. The study used subjective scoring and did not provide the type of placebo-controlled design expected for a definitive efficacy claim.
Reviews of Triphala in functional gastrointestinal disorders describe mild laxative activity and possible effects on motility, mucosal function, and intestinal microorganisms. Much of the mechanistic work, however, comes from extracts, isolated constituents, laboratory systems, or animal models. These findings do not establish that Triphala is non-habit-forming, that it cannot cause rebound symptoms, or that it is categorically different from all stimulant laxatives.
For occasional constipation, Triphala may be considered only after basic causes such as inadequate fluid or fibre intake, medication effects, painful fissures, thyroid disease, or other bowel disorders have been considered. Persistent constipation, bleeding, vomiting, unexplained weight loss, anaemia, severe pain, or sudden bowel changes require medical assessment.
Antioxidant Activity: Strongest in Laboratory Studies
Triphala and its three constituent fruits contain polyphenolic compounds, including gallic acid, ellagic acid, chebulagic acid, and chebulinic acid. A 2005 laboratory study found that Triphala’s constituents displayed free-radical reactions and antioxidant activity under different experimental conditions. This supports chemical antioxidant potential, but an in-vitro assay does not by itself demonstrate prevention or treatment of disease in people.
A 2016 cell study examined Triphala extract in human dermal fibroblasts and keratinocytes. The extract protected cultured cells against hydrogen-peroxide-related oxidative injury and reduced markers of DNA damage and cellular senescence under the tested conditions. The experiment did not demonstrate a clinical anti-ageing effect, did not measure outcomes in people, and was not a trial of oral Triphala for skin disease.
Evidence level: Consistent laboratory antioxidant activity is documented. Human biomarker and clinical-outcome data remain too limited and heterogeneous to support broad claims that routine Triphala supplementation prevents oxidative-stress-related disease.
Anti-Inflammatory Effects: Preclinical
In cultured macrophages, Triphala extract reduced the expression or production of inflammatory mediators including TNF-alpha, IL-1beta, IL-6, nitric oxide, iNOS, and COX-2. The same publication reported anti-inflammatory effects in an adjuvant-induced arthritis model in rats, associated with modulation of NF-kappaB signalling. These are mechanistic and animal findings rather than proof of benefit for human rheumatoid arthritis or osteoarthritis.
Triphala Guggulu is a separate multi-ingredient Ayurvedic formulation containing Triphala and processed Guggulu. Results obtained with Triphala Guggulu cannot be attributed to Triphala alone. Triphala should not replace diagnosis, disease-modifying treatment, analgesic planning, or physiotherapy for inflammatory joint disease.
Antimicrobial and Oral-Health Applications
Extracts of Triphala and its fruits have inhibited several microorganisms in laboratory experiments, with results depending on the solvent, concentration, organism, and test method. Such findings do not make oral Triphala a systemic antibiotic or antifungal treatment. The most clinically relevant antimicrobial application studied so far is its use as a mouth rinse for plaque and gingival inflammation.
In a 2014 double-blind randomized multicentre trial, 120 hospitalized patients were divided among distilled-water, 0.2% chlorhexidine, and Triphala mouth-rinse groups. Participants used 10 mL for one minute twice daily for two weeks. Triphala and chlorhexidine both reduced plaque and gingival index scores compared with the water control, and the trial found no significant efficacy difference between the two active rinses over that short period.
A later systematic review found Triphala mouthwashes more effective than placebo for gingivitis and found no statistically significant difference between Triphala and chlorhexidine across the included studies. Studies varied in concentration, duration, population, and quality. A standardized dental product may therefore be a possible adjunct to brushing and professional care, but it should not be presented as a proven replacement for chlorhexidine in every clinical situation.
Weight and Metabolic Outcomes: Preliminary and Heterogeneous
A 2012 double-blind randomized placebo-controlled trial enrolled 62 participants with obesity. The tested product was an Itrifal Saghir confection made from equal portions of the three fruits with almond oil and honey, taken as 5 g twice daily for 12 weeks. Compared with placebo, the intervention produced a reported between-group difference of 4.82 kg in weight loss, together with reductions in waist and hip circumference. This result applies to that specific confection and study population, not automatically to ordinary Triphala tablets or powder.
A 2021 systematic review of clinical studies reported favourable changes in some lipid, glucose, weight, body-mass-index, and waist-circumference outcomes, while also emphasizing the need for larger, well-designed randomized trials. The included studies differed in formulations, doses, populations, and methods. Triphala is therefore not an established stand-alone treatment for obesity, diabetes, or dyslipidaemia and should not displace nutrition, activity, sleep, behavioural care, or prescribed medication.
Anticancer Findings: Laboratory and Animal Research Only
Triphala extracts have been examined in cancer-cell and animal models. A 2015 study found that a methanol extract suppressed proliferation and induced apoptosis-related changes in human colon cancer stem cells and HCT116 colon cancer cells, including changes in c-Myc, cyclin D1, Bax, and Bcl-2-related signalling. The authors called for further in-vivo investigation.
Human anticancer efficacy has not been established in clinical trials. Triphala must not be promoted as a cancer treatment, a substitute for surgery, radiotherapy, chemotherapy, immunotherapy, endocrine therapy, or evidence-based prevention. A person with cancer should discuss every herbal product with the oncology team because supplements may affect symptoms, laboratory tests, treatment tolerance, or drug metabolism.
Dose and Formulation
There is no single clinically validated Triphala dose for all goals. Crude powder, tablets, aqueous extracts, alcoholic extracts, confections, and mouth rinses are not dose-equivalent. The amounts below describe studied exposures or safe-use boundaries, not universal prescriptions.
| Form or purpose | Documented exposure | How to interpret it |
|---|---|---|
| Traditional powder or tablets | Product- and practitioner-specific | Follow a quality-controlled label and individualized professional advice; tablet counts cannot be converted reliably without knowing extract strength. |
| Aqueous extract safety study | 2,500 mg daily for 4 weeks | Studied in a small group of healthy adults for short-term safety; not proof of long-term safety or efficacy. |
| Weight trial confection | 5 g twice daily for 12 weeks | A honey-and-almond-oil confection used under trial conditions; not a general weight-loss recommendation. |
| Clinical mouth rinse | 10 mL twice daily for 2 weeks in one trial | Use only a standardized oral product as directed by a dentist or its validated label; do not swallow. |
| Eye application | Home-prepared infusions are unsuitable | Anything placed in the eye must be sterile; powdered-herb infusions should not be used as eye drops or eye wash. |
Safety Profile
A small human safety study gave 2,500 mg per day of a standardized aqueous extract to healthy volunteers for four weeks and reported no serious adverse effects. Long-duration animal toxicology has also been reassuring at the tested doses. These findings support short-term tolerability of specified preparations, but they do not justify the claim that every Triphala product is proven safe for indefinite daily use.
Possible dose-related effects include loose stools, urgency, abdominal discomfort, or cramping. Stop use and seek advice if diarrhoea is persistent, dehydration develops, symptoms worsen, or an allergic reaction occurs. Safety during pregnancy, breastfeeding, and childhood has not been adequately established, so routine unsupervised use in these groups is inappropriate.
Laboratory and animal studies indicate that Triphala can influence some cytochrome P450 enzymes and drug transport processes, while direct clinically significant interactions in humans remain insufficiently characterized. People taking prescription medicines—especially drugs with a narrow therapeutic range or medicines for diabetes, blood pressure, clotting, seizures, transplantation, or cancer—should obtain advice from a physician or pharmacist before use.
The Bottom Line
Triphala is an authentic classical Ayurvedic formulation with a prominent rasayana and digestive role. Its most persuasive human data concern short-term oral-health use, while digestive benefits are supported by tradition and limited clinical studies. Antioxidant, anti-inflammatory, antimicrobial, and anticancer mechanisms are mainly laboratory or animal findings, and weight-related results come from small, heterogeneous trials.
The formulation should be valued without turning preclinical findings into treatment promises. Preparation, dose, and patient context matter. Consult a qualified Ayurvedic practitioner and healthcare provider before using Triphala for a chronic condition, during pregnancy or breastfeeding, in children, alongside prescription medicines, or as part of cancer care.
References
- Triphala Churna-A Traditional Formulation in Ayurveda Mitigates Diabetic Neuropathy in Rats (2021), PubMed Central
- Charaka Samhita — Rasayana Adhyaya
- Utoronto (utoronto.scholaris.ca)
- Triphala: current applications and new perspectives on the treatment of functional gastrointestinal disorders (2018), PubMed Central
- NIDDK
- In vitro antioxidant studies and free radical reactions of triphala, an ayurvedic formulation and its constituents (2005), PubMed
- Protective Effects of Triphala on Dermal Fibroblasts and Human Keratinocytes (2016), PubMed
- Triphala herbal extract suppresses inflammatory responses in LPS-stimulated RAW 264.7 macrophages and adjuvant-induced arthritic rats via inhibition of NF-κB pathway (2016), PubMed
- A randomized clinical trial to evaluate and compare the efficacy of triphala mouthwash with 0.2% chlorhexidine in hospitalized patients with periodontal diseases (2014), PubMed
- LWW Journals
- Link (link.springer.com)
- Effects of Triphala on Lipid and Glucose Profiles and Anthropometric Parameters: A Systematic Review (2021), PubMed
- Triphala Extract Suppresses Proliferation and Induces Apoptosis in Human Colon Cancer Stem Cells via Suppressing c-Myc/Cyclin D1 and Elevation of Bax/Bcl-2 Ratio (2015), PubMed
- Study of the safety of oral Triphala aqueous extract on healthy volunteers (2020), PubMed
- Safety of the Oral Triphala Recipe from Acute and Chronic Toxicity Tests in Sprague-Dawley Rats (2022), PubMed
- Inhibitory effects of Triphala on CYP isoforms in vitro and its pharmacokinetic interactions with phenacetin and midazolam in rats (2022), PubMed Central
- FDA
The 2000 years of continuous prescription qualifier is actually meaningful here. Triphala has more historical use data than almost any plant medicine and the absence of serious adverse effects over that period is itself a form of evidence that clinical trials can’t provide.
I liked the practical side of The Triphala Evidence. The practical details matter more than people think.
The combination-versus-single-herb question is something I’ve wondered about. Is the documented synergy between the three fruits reproducible in clinical settings or is it primarily theoretical based on in vitro data?
I’ve been taking Triphala for four years and the consistency of bowel function has been the main benefit. The oral health data is something I hadn’t read before. Started using Triphala water as a mouth rinse and the gum sensitivity has reduced noticeably.
I liked the practical side of The Triphala Evidence. I would still ask a practitioner before changing medicines.
Is the evidence reviewed here from standardized extract preparations or traditional powder preparations? The bioavailability difference is significant and comparing raw powder studies to standardized extract studies as if they’re equivalent would overstate the evidence.
The blood sugar modulation evidence is the section my husband needs to read. He has borderline glucose and I’ve been recommending Triphala but without being able to explain why. Now I can.
The immune system section deserves more evidence-quality nuance. The immunomodulatory data for Triphala is predominantly in vitro and animal studies. The clinical human evidence for immune function specifically is quite limited. Worth distinguishing from the gut and metabolic evidence which is stronger.
I liked the practical side of The Triphala Evidence. The timing advice is the part I would start with.
The breakdown of human trials versus lab data really clarifies where the evidence stands.
The decade of reviewing this literature adds a layer of credibility. Most herb evidence guides are written by people who read the abstract and summarize it. A practitioner who has followed a literature corpus for ten years can actually track how the evidence has evolved.
Using Triphala as a mouth rinse seems promising, but the article wisely notes it shouldn’t replace chlorhexidine yet.
One question that comes up: how does the equal-part powder compare to the confection used in the weight trial?
It’s interesting that the Charaka Samhita mentions individualized regimens, yet modern products often ignore that nuance.
After reading about the antioxidant assays, I wonder if any human studies have measured oxidative stress markers after supplementation.
A practical takeaway: start with a low dose and watch for digestive changes before increasing amount.
The part about The Triphala Evidence feels realistic. The article avoids making it sound like a quick fix.
@Rebecca that’s a fair point. I noticed the the anti-cancer preliminary findings approach varies by school
that’s a fair point. I noticed the Triphala for IBS data approach varies by school
Picked up a bottle of standardization issues last week but wasn’t sure about timing. Your dosage section helped.
yes! 5g nightly dose protocol worked similarly for me, thanks for sharing
Picked up the the 23 clinical trials overview prep from the section on seasonal variation. Results after 4 weeks: good.
Need this.
I notice you don’t mention any contraindications for the anti-cancer preliminary findings. That feels like an important omission.
I had the same issue. didn’t work well for me either
OT but curious if there’s a post on Ayurvedic approaches to thyroid issues?
Have you written anything about combining standardization issues with conventional medicine?
Picked up a bottle of the 23 clinical trials overview last week but wasn’t sure about timing. Your dosage section helped.
Good info.
What’s the difference between the the 23 clinical trials overview approach for acute vs chronic conditions?
omg the Triphala for IBS data part is exactly what i needed to read today
Been following this blog for a while and the the 23 clinical trials overview post is one of the most useful ones.
Started standardization issues six weeks ago after reading a different article, came here to compare approaches.
Not dismissing the anti-cancer preliminary findings entirely but it didn’t do much for me. My constitution might be different.
great info on the 23 clinical trials overview. the dosage breakdown is super clear
Started with the beginner dose mentioned in the Triphala for IBS data section. Two weeks in and digestion is smoother.
my ayurvedic doctor told me the same thing about the 23 clinical trials overview last month. glad to see it here
Started with the beginner dose mentioned in the standardization issues section. Two weeks in and digestion is smoother.
Have you written anything about combining the 23 clinical trials overview with conventional medicine?
Same here.
Can standardization issues be done at home or do you need a certified practitioner?
Is the 5g nightly dose protocol version from Kerala classical or is it more modern?
My grandmother used to do exactly what you described for the anti-cancer preliminary findings. Never had a name for it until now.
not convinced by the the anti-cancer preliminary findings argument. would need to see better evidence
The the 23 clinical trials overview schedule in section 2 , is that for all three doshas or specifically for Kapha?
Sharing this with my mother, she has been struggling with exactly what the the 23 clinical trials overview section describes.
At what point should someone stop self-administering Triphala for IBS data and see a vaidya?
bookmarked. the standardization issues section saved me so much confusion
some of the claims about the anti-cancer preliminary findings seem exaggerated. been in this space for years
Tried 5g nightly dose protocol for 6 weeks, honestly didn’t notice much. Maybe my dosage was off.
You mention 5g nightly dose protocol works for Vata types, but what about mixed Vata-Pitta constitutions?